Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell ...
1 (tie), Lauren Coughlin and Rio Takeda, 3. 3, 9 tied with 2. 1 (tie), Jaravee Boonchant, In Gee Chun, Jessica Porvasnik, Julia Lopez Ramirez, Miranda Wang and Fiona Xu, 1.00%. 7, Andrea Lee, .88%. 8, ...
Sanctuary Advisors LLC cut its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 57.9% ...
Plus: Maura Healey meets with eds-and-meds leaders about threats to research funding; Takeda sends zebras flying at Celtics ...
Protein S is a key vitamin K-dependent plasma protein involved in the regulation of coagulation. Deficiency of protein S, ...
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...
Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it ...
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...
Takeda Pharmaceutical teamed up with the Boston Celtics to raise awareness of rare diseases at the C’s-Cavaliers game on ...
GlobalData on MSN2d
Takeda and Protagonist report topline outcomes from trial of rusfertideTakeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback